Management of benign prostatic hyperplasia

Annual Review of Medicine

Volumn 48, Issue , 1997, Pages 177-189

  Barry, M ^a   Roehrborn, C ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adrenergic alpha antagonists; Finasteride; Prostate specific antigen; Prostatectomy; Prostatic hyperplasia

Indexed keywords

ANDROGEN; CREATININE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGING; CREATININE BLOOD LEVEL; DISEASE SEVERITY; HUMAN; MALE; MEDICAL DECISION MAKING; MORBIDITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; RESIDUAL URINE; REVIEW; RISK FACTOR; SYMPTOM; URINALYSIS; UROFLOWMETRY;

HUMANS; MALE; PATIENT CARE TEAM; PATIENT PARTICIPATION; PROSTATECTOMY; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINARY BLADDER NECK OBSTRUCTION; URODYNAMICS;

EID: 0031041107     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.48.1.177     Document Type: Review

References (40)

1. McConnell JD, Barry MJ, Bruskewitz RC, et al. 1994. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clin. Pract. Guidel. No. 8. AHCPR Publ. No. 94-0582. Rockville, MD: Agency Health Care Policy and Res., US Dept Health Human Serv.
2. Barry MJ, Cockett ATK, Holtgrewe HL, et al. 1993. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J. Urol. 150: 351-58
3. Yalla SV, Sullivan MP, Lecamwasam HS, et al. 1995. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J. Urol. 153:674-80
4. Abrams P. 1994. New words for old: lower urinary tract symptoms for "prostatism". Br. Med. J. 308:929-30
5. 1-adrenoreceptor selectivity? Br. J. Urol. 76(Suppl. 1):47-55
6. Garraway M, Collins G, Lee R. 1991. High prevalence of benign prostatic hypertrophy in the community. Lancet 338:469-71
7. Barry MJ. 1996. Epidemiology of benign prostatic hyperplasia. Am. Urol. Assoc. Update Series. In press
8. Ball AJ, Feneley RCL, Abrams PH. 1981. The natural history of untreated "prostatism". Br. J. Urol. 53:613-16
9. Barry MJ, Fowler FJ, O'Leary MP, et al. 1992. The American Urological Association Symptom Index for benign prostatic hyperplasia. J. Urol. 148:1549-57
10. Bruskewitz RC, Iversen P, Madsen PO. 1982. Value of postvoid residual urine determination in evaluation of prostatism. Urology 20:602-4
11. Abrams P. 1994. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urology 44:153-55
12. Catalona WJ, Richie JP, Ahmann FR, et al. 1994. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 151:1283-90
13. Sershon PD, Barry MJ, Oesterling JE. 1994. Serum prostate-specific antigen weakly discriminates between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur. Urol. 25:281-87
14. Crawford ED, Schutz MJ, Clejan S, et al. 1992. The effect of digital rectal examination on prostate-specific antigen levels. JAMA 267:2227-28
15. Oesterling JE, Jacobsen SJ, Chute CG, et al. 1993. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270:860-64
16. Benson MC, Whang IS, Pantuck A, et al. 1992. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 147:817-21
17. Carter HB, Pearson JD, Metter J, et al. 1992. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-20
18. Catalona WJ, Smith DS, Wolfert RL, et al. 1995. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274:1214-20
19. Eri L, Tveter KJ. 1995. Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia. J. Urol. 154:923-34
20. Roehrborn CG, Oesterling JE, Auerbach S, et al. 1996. The Hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47:159-68
21. Gormley GJ, Stoner E, Bruskewitz RC, et al. 1992. The effect of finasteride in men with benign prostatic hyperplasia. N. Engl. J. Med. 327:1185-91
22. Lepor H. 1996. A Department of Veterans Affairs (VA) cooperative randomized placebo controlled clinical trial of the safety and efficacy of terazosin and finasteride monotherapy and terazosin/finasteride combination therapy in men with clinical BPH. J. Urol. 155:587A (Abstr.)
23. Lepor H. 1996. Does prostate volume (PV) predict response to terazosin and finasteride monotherapy and terazosin/finasteride combination therapy? A subset analysis of the VA Cooperative BPH Medical Therapy Study. J. Urol. 155:574A (Abstr.)
24. Boyle P, Gould AL. 1996. Prostate volume predicts outcome of treatment of BPH with finasteride: meta-analysis of randomized clinical trials. J. Urol. 155:572A (Abstr.)
25. McConnell JD. 1995. Prostatic growth: new insights into hormonal regulation. Br. J. Urol. 76(Suppl. 1):5-10
26. Guess HA, Heyse JF, Gormley GJ, et al. 1993. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase III clinical trial. Urol. Clin. North Am. 20:627-36
27. Fowler FJ, Wennberg JE, Timothy RP, et al. 1988. Symptom status and quality of life following prostatectomy. JAMA 259: 3018-22
28. Neal DE, Ramsden PD, Sharples L, et al. 1989. Outcomes of elective prostatectomy. Br. Med. J. 299:762-67
29. Wasson JH, Reda DJ, Bruskewitz RC, et al. 1995. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N. Engl. J. Med. 332:75-79
30. Jonler M, Bruskewitz RC. 1994. Transurethral incision of the prostate. Curr. Opinion Urol. 4:29-31
31. Gerber GS. 1995. Lasers in the treatment of benign prostatic hyperplasia. Urology 45: 193-99
32. Cowles RS, Kabalin JN, Childs S, et al. 1995. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. Urology 46: 155-60
33. Anson K, Nawrocki J, Buckley J, et al. 1995. A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. Urology 46:305-10
34. Narayan P, Tewari A, Aboseif S, Evans C. 1995. A randomized study of visual laser ablation and transurethral evaporation of the prostate in the management of benign prostatic hyperplasia. J. Urol. 154:2083-88
35. Kaplan SA, Te AE. 1995. Transurethral electrovaporization of the prostate: a novel method for treating men with benign prostatic hyperplasia. Urology 45:566-72
36. Kaplan SA, Te AE. 1995. A comparative study of transurethral resection of the prostate using a modified electro-vaporizing loop and transurethral laser vaporization of the prostate. J. Urol. 154:1785-90
37. Ogden CW, Reddy P, Johnson H, et al. 1993. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic outflow obstruction. Lancet 341:14-17
38. Dahlstrand C, Walden M, Geirsson G, Pettersson S. 1995. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br. J. Urol. 76: 614-18
39. Kaplan SA, Merrill DC, Moseley WG, et al. 1993. The titanium intraprostatic stent: the United States experience. J. Urol. 150: 1624-29
40. Oesterling JE, Kaplan SA, Epstein HB, et al. 1994. The North American experience with the Urolume endoprosthesis as a treatment for benign prostatic hyperplasia: long-term results. Urology 44:353-62